Results 21 to 30 of about 14,813,386 (261)

How CAR T Cells Breathe

Cells, 2022
The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism. T cells tend to adopt diverse metabolic profiles depending on their differentiation state and their stimulation level.
Christopher Forcados, Sandy Joaquina, Nicholas Paul Casey, Benjamin Caulier, Sébastien Wälchli   +4 more
openaire   +4 more sources

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma

Turkish Journal of Hematology, 2023
Cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are significant complications in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing chimeric antigen receptor T-cell (CAR-T cell ...
Christian Messerli, Gertrud Wiedemann, Naomi Porret, Michael Nagler, Katja Seipel, Barbara Jeker, Urban Novak, Sacha Zeerleder, Ulrike Bacher, Thomas Pabst   +9 more
doaj   +1 more source

Donor T cells for CAR T cell therapy

Biomarker Research, 2022
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed.
Tiffany C. Y. Tang, Ning Xu, Robert Nordon, Michelle Haber, Kenneth Micklethwaite, Alla Dolnikov   +5 more
doaj   +1 more source

Counteracting CAR T cell dysfunction [PDF]

Oncogene, 2021
AbstractIn spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in vivo, conceivably induced by immunosuppressive tumor microenvironment (TME) and excessive antigen exposure.
Mansour Poorebrahim, Jeroen Melief, Yago Pico de Coaña, Stina L. Wickström, Angel Cid-Arregui, Rolf Kiessling   +5 more
openaire   +2 more sources

Impact of Manufacturing Procedures on CAR T Cell Functionality

Frontiers in Immunology, 2022
The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in the past few decades. As of today, there are six CAR T cell products that have been approved by the FDA: KYMRIAH (tisagenlecleucel, CD19 CAR T cells), YESCARTA ...
Norihiro Watanabe, Feiyan Mo, Feiyan Mo, Mary Kathryn McKenna   +3 more
doaj   +1 more source

Mediport use as an acceptable standard for CAR T cell infusion

Frontiers in Immunology, 2023
IntroductionMediport use as a clinical option for the administration of chimeric antigen receptor T cell (CAR T cell) therapy in patients with B-cell malignancies has yet to be standardized.
Maya Eylon, Snehit Prabhu, Samuel John, Maxwell J. M. King, Dhruv Bhatt, Kevin J. Curran, Courtney Erickson, Nicole A. Karras, Christine L. Phillips, Christine L. Phillips, Prakash Satwani, Michelle Hermiston, Erica Southworth, Susanne H. C. Baumeister, Julie-An Talano, Margaret L. MacMillan, Jenna Rossoff, Challice L. Bonifant, Gary Doug Myers, Rayne H. Rouce, Keri Toner, Timothy A. Driscoll, Emmanuel Katsanis, Dana B. Salzberg, Deborah Schiff, Satiro N. De Oliveira, Christian M. Capitini, Holly L. Pacenta, Holly L. Pacenta, Thomas Pfeiffer, Niketa C. Shah, Van Huynh, Jodi L. Skiles, Ellen Fraint, Kevin O. McNerney, Troy C. Quigg, Joerg Krueger, John A. Ligon, Vanessa A. Fabrizio, Christina Baggott, Theodore W. Laetsch, Liora M. Schultz   +41 more
doaj   +1 more source

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. [PDF]

, 2022
Chimeric antigen receptor T-cells (CAR T) treatment has become a standard option for patients with diffuse large B-cell lymphomas (DLBCL), which are refractory or relapse after two prior lines of therapy.
Rentsch, Vera, Pabst, Thomas, Porret, Naomi, Katja Seipel, Thomas Pabst, Wiedemann, Gertrud, Gertrud Wiedemann, Naomi Porret, Banz, Yara, Ulrike Bacher, Vera Rentsch, Seipel, Katja, Bacher, Ulrike, Yara Banz   +13 more
core   +2 more sources

Strategies to enhance CAR-T persistence

Biomarker Research, 2022
Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma.
Yue Liu, Lingna An, Ruihao Huang, Jingkang Xiong, Haoyu Yang, Xiaoqi Wang, Xi Zhang   +6 more
doaj   +1 more source

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function

Frontiers in Immunology, 2022
The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and exhaustion markers, affects the long-term functionality of CAR-T cells.
Masaya Suematsu, Shigeki Yagyu, Nobuyoshi Nagao, Susumu Kubota, Yuto Shimizu, Miyuki Tanaka, Yozo Nakazawa, Toshihiko Imamura   +7 more
doaj   +1 more source

Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia

, 2021
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the clinical treatment of hematological malignancies due to the prominent anti-tumor effects. B cell maturation antigen (BCMA) CAR-T cells have demonstrated promising effects in patients
Weiskittel, TM, Luo, Q, Yu, H, Chang, AH, Guo, X, Li, H, Ding, L, Cui, J, Xu, X, Zhang, Y, Wei, G, Shao, M, Hu, Y, Huang, H, Li, X, Teng, X, Xu, H, Wu, W, Ritchie, ME, He, J, Zhu, Y, Zhang, J   +21 more
core   +1 more source